share_log

Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $4

Benzinga ·  Mar 7 09:30

Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $3 to $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment